Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREVI-OC-03 maintenance study in platinum-sensitive relapsed ovarian cancer
jRCT2051260183Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Torvutatug samrotecan maintenance, Torvutatug samrotecan plus bevacizumab maintenance and Standard of care maintenance (3 arms). Primary endpoint: Progression-free survival. Started Sep 2026; status: recruiting.
02
Drugs
torvutatug samrotecanbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2051260183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260183.